Clovis Oncology announces European Commission OK of Rubraca for ovarian cancer
BOULDER -- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced the European Commission (EC) has approved the use of Rubraca(rucaparib) for treatment of ovarian cancer. Specifically, the... Read More
Monday January 28, 2019 0 comments
Clovis Oncology announces positive hearing for Rubraca in Europe
BOULDER -- Clovis Oncology, Inc. (NASDAQ:CLVS) today announced after opposition proceedings at The Hague, Netherlands, that the European Patent Office upheld claims of European Patent 2534153... Read More
Wednesday December 5, 2018 0 comments
Clovis Oncology announces second patent for Rucaparib high dose
BOULDER -- Clovis Oncology , Inc. (NASDAQ:CLVS) today announced the United States Patent and Trademark Office issued United States Patent 10,130,636 with claims directed to methods of treating... Read More
Tuesday November 20, 2018 0 comments
Clovis Oncology announces European authorization of rucaparib for ovarian cancer care
BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS) today announced the European Commission (EC) has authorized Rubraca (rucaparib) as monotherapy treatment of adult patients with... Read More
Tuesday May 29, 2018 0 comments
Clovis Oncology offering convertible senior notes, stocks to raise up to $345M
BOULDER -- Clovis Oncology, Inc .(NASDAQ:CLVS) announced it has commenced two separate underwritten public offerings of convertible senior notes and common stock to raise a total of $345... Read More
Monday April 16, 2018 0 comments
Clovis: EU Medicines Agency approval sought for rucaparib cancer drug
BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS) today announced the European Unions (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has requested that... Read More
Tuesday December 19, 2017 0 comments
Clovis Oncology submits NDA for rucaparib to treat recurrent ovarian cancer
BOULDER -- Clovis Oncology (NASDAQ: CLVS) today announced it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for rucaparib as maintenance... Read More
Tuesday October 10, 2017 0 comments
Clovis Oncology: Rucaparib improved survival in ovarian cancer patients
BOULDER -- ClovisOncology (NASDAQ: CLVS) today announced toplinedata from the confirmatory phase 3 ARIEL3 trial of rucaparib, which successfully achievedthe primary endpoint of improved... Read More
Monday June 19, 2017 0 comments
- 1
- 2
IN Sponsors
Browse
Entrepreneurial by Nature
